Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.49 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.49 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.49 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | ESPL1 | Q14674 | 1/20 | 0.39 |
| ▸ | PTGES | O14684 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MITF | O75030 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29435964 | 1.00 | ALDH1A1 (0.49) | ALDH1A1HIF1ATDP1TSHRCYP3A4 | |
| SCHEMBL5605388 | 0.94 | ALDH1A1 (0.44) | ALDH1A1HIF1ATDP1TSHRCYP3A4 | |
| SCHEMBL31297346 | 0.86 | ALDH1A1 (0.46) | ALDH1A1HIF1ATDP1TSHRCYP3A4 | |
| SCHEMBL3077114 | 0.86 | ALDH1A1 (0.46) | ALDH1A1HIF1ATDP1TSHRCYP3A4 | |
| SCHEMBL602444 | 0.85 | TSHR (0.52) | ALDH1A1HIF1ATDP1TSHRCYP3A4 | |
| SCHEMBL29672221 | 0.85 | TSHR (0.52) | ALDH1A1HIF1ATDP1TSHRCYP3A4 | |
| SCHEMBL17375037 | 0.84 | ALDH1A1 (0.44) | ALDH1A1HIF1ATDP1TSHRCYP3A4 | |
| SCHEMBL31510262 | 0.83 | TDP1 (0.47) | ALDH1A1HIF1ATDP1TSHRCYP3A4 | |
| SCHEMBL8043011 | 0.83 | TDP1 (0.47) | ALDH1A1HIF1ATDP1TSHRCYP3A4 | |
| SCHEMBL30568358 | 0.81 | PTGES (0.46) | ALDH1A1HIF1ATDP1TSHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1853548-A1 | PROCESS FOR THE PREPARATION OF BENZOIC ACID DERIVATIVES VIA A NEW INTERMEDIATE OF SYNTHESIS | MITENI S.p.A. (IT) | 2007-11-14 | — | — | EP | claimed |
| WO-2006090210-A1 | PROCESS FOR THE PREPARATION OF BENZOIC ACID DERIVATIVES VIA A NEW INTERMEDIATE OF SYNTHESIS | MITENI S.P.A. (IT) | 2006-08-31 | — | — | WO | claimed |
| CN-112955436-B | 6-oxo-1, 6-dihydropyridazine derivatives, preparation method and application thereof in medicines | 福建盛迪医药有限公司 | 2023-08-11 | — | — | CN | disclosed |
| CN-112955436-A | 6-oxo-1, 6-dihydropyridazine derivatives, preparation method and application thereof in medicines | 江苏恒瑞医药股份有限公司 | 2021-06-11 | — | — | CN | disclosed |
| US-8859574-B2 | Compounds and compositions as kinase inhibitors | IRM LLC (BM) | 2014-10-14 | — | — | US | disclosed |
| US-20130310361-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2013-11-21 | — | — | US | disclosed |
| US-8519129-B2 | Pyrimidine derivatives as kinase inhibitors | IRM LLC (BM) | 2013-08-27 | — | — | US | disclosed |
| CN-101891624-B | Method for preparing benzotrifluoride derivative | BASF SE | 2013-05-01 | — | — | CN | disclosed |
| US-20110112063-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2011-05-12 | — | — | US | disclosed |
| EP-2318392-A2 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2011-05-11 | — | — | EP | disclosed |
| WO-2010002655-A2 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2010-01-07 | — | — | WO | disclosed |
| US-20090253688-A1 | Semicarbazide derivatives as kinase inhibitors | MERCK PATENT GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
| EP-1853548-B1 | PROCESS FOR THE PREPARATION OF BENZOIC ACID DERIVATIVES VIA A NEW INTERMEDIATE OF SYNTHESIS | MITENI SPA (IT) | 2009-05-13 | — | — | EP | disclosed |
| EP-1853548-A1 | PROCESS FOR THE PREPARATION OF BENZOIC ACID DERIVATIVES VIA A NEW INTERMEDIATE OF SYNTHESIS | MITENI S.p.A. (IT) | 2007-11-14 | — | — | EP | disclosed |
| US-20070191423-A1 | Isoquinoline derivatives | MERCK PATENT GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| US-20070161677-A1 | Bisarylurea derivatives | MERCK PATENT GMBH (DE) | 2007-07-12 | — | — | US | disclosed |
| WO-2006090210-A1 | PROCESS FOR THE PREPARATION OF BENZOIC ACID DERIVATIVES VIA A NEW INTERMEDIATE OF SYNTHESIS | MITENI S.P.A. (IT) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161677-A1 | Bisarylurea derivatives | BRAF, RAF1, NRAS | ALDH1A1 764/4885HIF1A 1843/4885TDP1 835/4885 |
| US-20130310361-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IGF1R, IRS1, IP6K1 | ALDH1A1 975/4885HIF1A 1022/4885TDP1 803/4885 |
| US-20070191423-A1 | Isoquinoline derivatives | ABL1, MAP3K1, MAP3K2 | ALDH1A1 2329/4885HIF1A 899/4885TDP1 1060/4885 |
| US-20090253688-A1 | Semicarbazide derivatives as kinase inhibitors | MAP3K1, MAP3K6, MAP3K2 | ALDH1A1 1023/4885HIF1A 1498/4885TDP1 2019/4885 |
| US-20110112063-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IGF1R, TYMP, PDXK | ALDH1A1 573/4885HIF1A 838/4885TDP1 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.